MPR Weekly Dose

MPR Weekly Dose MPR 121 — New Treatment for Crohn Disease; USPSTF Recommendations on Vitamins for CVD, CA Prevention; Panel Vote on Alzheimer Tx; Phexxi Analysis; Vaxneuvance Approved for Pediatrics

Jun 24, 2022

Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.

MPR Weekly Dose MPR 120 — Child COVID Vaccine Vote; Alopecia Tx Approved; Paxlovid in Standard Risk Patients; Autism Diagnostic Aid; Polyneuropathy hATTR Amyloidosis

Jun 17, 2022

FDA panel vote on COVID vaccines for young children; new drug approved to treat alopecia; paxlovid tested in standard risk individuals; a device to aid autism diagnosis; and a new approval for polyneuropathy hATTR.

MPR Weekly Dose MPR 119 — FDA Panel Votes on Novavax; MMR Vaccination; Dupixent Approval Expanded; Investigative COVID-19 Treatments

Jun 10, 2022

The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.

MPR Weekly Dose 118 — Ukoniq Approval Withdrawn; Rescue Inhaler to Be Reviewed; Dupilumab Priority Review; Kymriah Update; Novel Postpartum Depression Tx Shows Promise

Jun 3, 2022

Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depression treatment.